Contact us | Add to favorites | Association address | Related link
Welcome to 2024/3/28 9:18:40
homepage About the Association Association dynamics Policies and regulations Beijing Medicine Express Industry dynamics International information Economic analysis Thematic discussion At your service Training registration Branch garden Social organization
Job column
  Current Location:首页>>International information>>International information
Bristol-myers Squibb acquires MyoKardia for $13.1 billion in cash

        11Bristol Myers Squibb (BMS) today announced that it has successfully completed the sale of MyoKardia, Inc .For $13.1 billion in all cash。Upon completion of the acquisition, MyoKardia's shares ceased trading on the NASDAQ Global Select Market and became a wholly-owned subsidiary of BMS。

Bristol-myers Squibb's previously announced offer to acquire all of MyoKardia's outstanding common stock for $225 per share expired at 12:00 am New York time on November 16, 2020。Approximately 42 million common shares were valiantly tendered and were not withdrawn from the offer, representing approximately 78 percent of MyoKardia's outstanding common shares.9%。Accordingly, under the terms of the tender offer, all validly tendered shares which are not duly withdrawn are subject to payment and BMS Party wishes to pay all such shares immediately。
Upon completion of the tender offer, BMS will further pass through Gotham Merger Sub Inc.The merger with MyoKardia, the result of which is the conversion of each issued and unissued share of MyoKardia common stock in the Offer into cash rights equal to $225, without pending a vote on the MyoKardia shareholder structure under Delaware Corporate law。
Through the acquisition of MyoKardia,BMS will receive MyoKardia's mavacamten drug,This is a potential first-in-class cardiovascular drug for the treatment of hypertrophic obstructive cardiomyopathy (HCM),Hypertrophic obstructive cardiomyopathy is a chronic heart disease with high incidence and high patient impact。Based on data from the EXPLORER-HCM study, a new drug application for mavacamten for the treatment of obstructive HCM is expected to be submitted to the U.S. Food and Drug Administration in the first quarter of 2021。
BMSWith this acquisition,It is hoped to explore the full potential of mavacamten in other indications, including non-obstructive hypertrophic cardiomyopathy,And develop MyoKardia's other novel compound product lines with great potential,These include two therapies that are currently in the clinical stage: danicamtiv (formerly known by the codename MYK-491) and MYK-224,And two preclinical therapies: ACT-1 and LUS-1。
(Information source: Sina Medicine)
(2020/11/20 14:56:09 Read 23054 times)

Beijing Pharmaceutical Industry Association public number

Copyright 2003-2016 percentred by Beijing Pharmaceutical Professiion Association All Rights Reserved
Copyright Beijing Pharmaceutical Industry Association. All rights reserved
ICP record number: Beijing ICP No. 11016038-1